The Severe Combined Immune Deficiency (SCID) drugs in development market research report provides comprehensive information on the therapeutics under development for Severe Combined Immune Deficiency (SCID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Severe Combined Immune Deficiency (SCID). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Severe Combined Immune Deficiency (SCID) and features dormant and discontinued products.

GlobalData tracks 20 drugs in development for Severe Combined Immune Deficiency (SCID) by 16 companies/universities/institutes. The top development phase for Severe Combined Immune Deficiency (SCID) is phase ii with 11 drugs in that stage. The Severe Combined Immune Deficiency (SCID) pipeline has nine drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Severe Combined Immune Deficiency (SCID) pipeline products market are: Boston Children’s Hospital, Mustang Bio and Shenzhen Geno-Immune Medical Institute.

The key targets in the Severe Combined Immune Deficiency (SCID) pipeline products market include Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG), Adenosine Deaminase (Adenosine Aminohydrolase or ADA or EC 3.5.4.4), and Protein Artemis (DNA Cross Link Repair 1C Protein or Protein A SCID or SNM1 Homolog C or SNM1 Like Protein or DCLRE1C or EC 3.1.).

The key mechanisms of action in the Severe Combined Immune Deficiency (SCID) pipeline product include Cytokine Receptor Common Subunit Gamma (Interleukin 2 Receptor Subunit Gamma or GammaC or p64 or CD132 or IL2RG) Activator with three drugs in Phase II. The Severe Combined Immune Deficiency (SCID) pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Severe Combined Immune Deficiency (SCID) pipeline products market including Gene-Modified Cell Therapy, and Cell Therapy.

Severe Combined Immune Deficiency (SCID) overview

Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections. The condition is fatal, usually within the first year or two of life, unless infants receive immune-restoring treatments such as transplants of blood-forming stem cells, gene therapy, or enzyme therapy.

For a complete picture of Severe Combined Immune Deficiency (SCID)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.